Cost of type 2 diabetes in Germany over 8 years (the ROSSO study No. 2)

References

• Thefeld W. [Prevalence of diabetes mellitus in the adult German population.] Gesundheitswesen 1999; 61 Spec. No: S85– S89 [in German].
   Google Scholar
• Rathmann W, Haastert B, Icks A et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA Survey 2000. Diabetologia 2003; 46: 182–189.
   Google Scholar
• International Diabetes Federation. Diabetes Atlas, 2nd edn. Brussels, Belgium: International Diabetes Federation, 2003.
   Google Scholar
• Liebl A, Neiss A, Spannheimer A et al. [Costs of type 2 diabetes in Germany. Results of the CODE-2 Study.] Deutsche Medizinische Wochenschrift 2001; 126: 585–589 [in German].
   Google Scholar
• Hauner H, Koster I, von Ferber L. [Prevalence of diabetes mellitus in Germany 1998–2001. Secondary data analysis of a health insurance sample of the AOK in Hesse/KV in Hesse.] Deutsche Medizinische Wochenschrift 2003; 128: 2632–2637 [in German].
   Google Scholar
• Hauner H, Koster I, von Ferber. [Outpatient care of patients with diabetes mellitus in 2001. Analysis of a health insurance sample of the AOK in Hesse/KV in Hesse.] Deutsche Medizinische Wochenschrift 2003; 128: 2638– 2643.
   Google Scholar
• Martin S, Schneider B, Heinemann L et al; for the ROSSO Study Group. Self-monitoring of blood glucose in type 2 diabetes and long- term outcome: an epidemiological cohort study. Diabetologia 2006; 49: 271–278.
   Google Scholar
• Hinzpeter B, Klever-Deichert G, Wendland G et al. [Coronary disease and social security. A simulation model on cost analysis.] Herz 2000; 5: 515–525 [in German].
   Google Scholar
• Szucs TD, Schwenkglenks M, Paschen B et al. [Cost effectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study.] Medizinische Klinik 2000; 95: 663–671 [in German].
   Google Scholar
• Banz K, Dinkel R, Hanefeld M, et al. Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus. A decision-analytical approach. Pharmacoeconomics 1998; 13: 449–459.
   Google Scholar
• Laaser U, Breckenkamp J, Niermann U. Cost- effectiveness-analysis of medical interventions in patients with stroke in Germany under special consideration of ‘stroke units’. Gesundheitsökonomie und Qualitätsmanagement 1999; 4: 176–183.
   Google Scholar
• Szucs TD, Guggenberger G, Berger K, et al. [Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study.] Herz 1998; 23: 319–329 [in German].
   Google Scholar
• Holler D, Claes C, der Schulenburg JM. Treatment costs and quality of life of patients with peripheral arterial occlusive disease — the German perspective. VASA 2004; 33: 145– 153.
   Google Scholar
• Ghatnekar O, Willis M, Persson U. Cost- effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries. Journal of Wound Care 2002; 11: 70–74.
   PubMedGoogle Scholar
• Dahmen HG. [Diabetic foot syndrome and its risks: amputation, handicap, high-cost sequelae.] Gesundheitswesen 1997; 59: 566–568 [in German].
   Google Scholar
• Szucs TD, Smala AM, Fischer T. [Costs of intensive insulin therapy in type 1 diabetes mellitus. Experiences from the DCCT study.] Fortschritte der Medizin 1998; 116: 34–38 [in German].
   Google Scholar
• Gozzoli V, Palmer AJ, Brandt A et al. [Increased clinical and economic advantages using PROSIT (proteinuria screening and intervention) in type 2 diabetic patients.] Deutsche Medizinische Wochenschrift 2000; 125: 1154–1159 [in German].
   Google Scholar
• Gesundheitsbericht für Deutschland 1998. In: Statistisches Bundesamt, editor. Wiesbaden: Metzler-Poeschel, 1998: pp. 341–345.
   Google Scholar
• Salize HJ, Stamm K, Schubert M, Bergmann F et al. [Cost of care for depressive disorders in primary and specialized care in Germany.] Psychiatrische Praxis 2004; 31: 147–156 [in German].
   Google Scholar
• Rathmann W, Haastert B, Giani G. [Drug prescriptions and costs in diabetic polyneuropathy.] Deutsche Medizinische Wochenschrift 1999; 124: 681–686 [in German].
   Google Scholar
• Available at: http://www.krankenhaus-aok. de/m02/m02_05/ [accessed 18 April 2005].
   Google Scholar
• Arzneiverordnungsreport 2004. Berlin, Heidelberg: Springer, 2004.
   Google Scholar
• Available at: http://www.oecd.org/ dataoecd/13/53/31963451.xls [accessed 18 April 2005].
   Google Scholar
• Häussler B, Berger U. Bedingungen für effektive Disease-Management-Programme. Analyse, Bewertung und Lösungsansätze für Qualität und Finanzierung. Berlin: IGES, 2005.
   Google Scholar
• Statistisches Jahrbuch 2004 für die Bundesrepublik Deutschland. Wiesbaden: Statistisches Bundesamt, 2004.
   Google Scholar
• Jonsson B. Revealing the cost of type 2 diabetes in Europe. Diabetologia 2002; 45: S5–12.
   PubMed Web of Science ®Google Scholar
• O’Brien JA, Shomphe LA, Kavanagh PL et al. Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 1998; 21: 1122–1128.
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Legood R et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Medicine 2003; 20: 442–450.
   Google Scholar